• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of toxicological sciences >Long-term comparative study of Substance-P with methylprednisolone on the development of osteoporosis
【24h】

Long-term comparative study of Substance-P with methylprednisolone on the development of osteoporosis

机译：P物质与甲基强的松龙对骨质疏松症发展的长期比较研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Steroids are treated for most inflammatory diseases but cause serious side effects such as diabetes and osteoporosis after their long-term usage. Recently, we identified novel roles of Substance-P (SP) in the suppression of the injury-mediated inflammation and also in stem cell mobilization. In this study, for clinical application of SP as an anti-inflammatory agent, its safety in long-term usage was evaluated with regard to diabetes and osteoporosis. Dexamethasone (DEX) and methylprednisolone (MP) were used as comparative drugs. While DEX-injection for 24 weeks developed severe weight loss, unstable blood glucose, and bone loss, SP-injection did not affect blood glucose and bone mass. MP-injection for 24 weeks also influenced blood glucose and body weight much milder than DEX-injection. After 66 weeks, MP-injection caused unstable blood glucose, alleviation in the age-related increase of body weight, and bone weakness, which was featured by reduction in collagen deposition and trabecular bone volume based on histological and micro CT analysis. However, SP-injection for 66 weeks rather increased collagen deposition, bone volume, and bone density. Therefore, this comparative study suggests that SP, even after long-term usage of effective dose, may not cause side effects such as osteoporosis in comparison to that of DEX and MP and can be developed as an anti-inflammatory agent and/or stem cell mobilizer for long-term treatment.
机译：类固醇可治疗大多数炎性疾病，但长期使用后会引起严重的副作用，例如糖尿病和骨质疏松症。最近，我们确定了Substance-P（SP）在抑制损伤介导的炎症以及干细胞动员中的新作用。在这项研究中，对于SP作为抗炎药的临床应用，针对糖尿病和骨质疏松症评估了其长期使用的安全性。地塞米松（DEX）和甲基泼尼松龙（MP）被用作对比药物。注射DEX 24周后会出现严重的体重减轻，血糖不稳定和骨丢失，而SP注射则不影响血糖和骨量。 MP注射24周对血糖和体重的影响也比DEX注射轻得多。 66周后，MP注射引起血糖不稳定，减轻了与年龄有关的体重增加和骨骼无力，其特征是根据组织学和显微CT分析，胶原蛋白沉积和小梁骨体积减少。然而，SP注射66周反而增加了胶原蛋白的沉积，骨量和骨密度。因此，该比较研究表明，与DEX和MP相比，即使长期使用有效剂量的SP也不会引起诸如骨质疏松症的副作用，并且可以被开发为抗炎药和/或干细胞。动员者可长期治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号